<DOC>
	<DOCNO>NCT00452361</DOCNO>
	<brief_summary>This study evaluate whether conversion cyclosporine , calcineurin inhibitor ( CI ) sirolimus ( SRL ) result improve long-term renal function without negative impact safety immunosuppressive efficacy , examine potential SRL reduce severity and/or progression chronic allograft nephropathy ( CAN ) .</brief_summary>
	<brief_title>Study Evaluating Calcineurin Inhibitors Versus Sirolimus Renal Allograft Recipient</brief_title>
	<detailed_description>This open-label , randomize , parallel-group , comparative , outpatient study conduct multiple center Taiwan . The study randomize approximately 120 patient . 80 patient randomize SRL therapy group ( conversion CI- SRL-based immunosuppression : group A ) 40 patient CI therapy group ( continue CI therapy : group B ) . Dosage Administration SRL Therapy : At time randomization day 1 , patient receiving : - triple therapy CI ( tacrolimus CsA ) begin time transplantation within 2 week thereafter AND - corticosteroid correspond dosage range 2.5 15 mg/day prednisone prednisolone ( 2 12 mg/day methylprednisolone ) alternate day equivalent least 12 week randomization , PLUS - either MMF ( minimum dose 500 mg/day ) /MPS ( minimum dose 360 mg/day ) AZA ( minimum dose 50 mg/day ) least 12 week randomization . SRL add immunosuppressive regimen Group A . Group B continue CI immunosuppressive regimen .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Calcineurin Inhibitors</mesh_term>
	<criteria>Subjects must least 18 year age . Subjects 6 60 month renal transplantation . Subjects stable graft function . Subjects active major infection , include HIV , decrease platelet , elevate lipid , multiple organ transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>